A commentary notes that although pharmacokinetic–pharmacodynamic considerations are complicated and call for subgrouping of patients by many factors, this meta-analysis does show that for many ß-lactams, different patients and different infections, prolonged infusion of β-lactams in ICU reduced in-hospital mortality. It adds that prolonged infusion is easy to apply in ICU settings and it could foresee no harm with this regimen and none has been shown. It suggests that based on current evidence base, prolonged dosing of β-lactams in ICUs should be standardised.